U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07853378) titled 'Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis' on Sept. 26.
Brief Summary: Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, characterized by fluctuating muscle weakness and fatigue. Surgical removal of the thymus gland (thymectomy) is an established treatment to help achieve disease control in eligible patients. However, surgery does not guarantee permanent remission, and some individuals experience disease recurrence or clinical worsening.
The main objective of this observational study is to determine the incidence and clinic...